GRCE Grace Therapeutics, Inc.
Grace Therapeutics, Inc. (GRCE) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: September 9, 2026 , by Opaleye Management Inc. .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Kohli Prashant | Chief Executive Officer | Buy | 100,000 | $2.14 | $214.0K | 121,357 | |
| Opaleye Management Inc. | 10% Owner | Buy | 5,836 | $2.09 | $12.2K | 2,775,229 | |
| Opaleye Management Inc. | 10% Owner | Buy | 9,393 | $2.10 | $19.7K | 2,769,393 | |
| Opaleye Management Inc. | 10% Owner | Buy | 11,608 | $2.09 | $24.2K | 2,760,000 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.